Kinacia was a Victorian biotechnology company established to commercialise a set of discoveries relating to blood clotting and thrombosis emerging from research conducted at Monash University's Australian Centre for Blood Diseases (ACED).
Despite technical success (the IP was eventually sold to Astra Zeneca) and targeting a major commercial opportunity, the company was not successful This chapter presents the initial years of the company's history, leading up to a change in the company's leadership taking place in early 2002.
| Original language | English |
|---|
| Title of host publication | Measured success |
|---|
| Subtitle of host publication | innovation management in Australia |
|---|
| Editors | Peter Cebon |
|---|
| Place of Publication | Carlton, Vic. |
|---|
| Publisher | Melbourne University Press |
|---|
| Pages | 166-182 |
|---|
| ISBN (Print) | 9780522855708 |
|---|
| Publication status | Published - 2008 |
|---|
| Name | MUP academic monograph series |
|---|
| Publisher | Melbourne University Press |
|---|